Cited by 946PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Open access

Konstantinopoulos, Panagiotis A., Ceccaldi, Raphael, Shapiro, Geoffrey I., D'Andrea, Alan D.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0714PMC PMC4631624

Open this paper in CoChat — free account

Abstract

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0714

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Show all 180 references

Sorted by citations

Items 401–500 of 946

Next-Generation Sequencing: Role in Gynecologic Cancers
Evans, T., & Matulonis, U. A. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0123 · Cited by 18
The Ethnic-Specific Spectrum of Germline Nucleotide Variants in DNA Damage Response and Repair Genes in Hereditary Breast and Ovarian Cancer Patients of Tatar Descent
Brovkina, O., Shigapova, L. H., Chudakova, D. A., Gordiev, M., Фаридович, Е. Р., Druzhkov, M., Ходырев, Д. С., Shagimardanova, E. I., Nikitin, A. G., & Gusev, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00421 · Cited by 20
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
Turinetto, M., Scotto, G., Tuninetti, V., Giannone, G., & Valabrega, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.689829 · Cited by 19
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment
Genta, S., Martorana, F., Stathis, A., & Colombo, I. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103539 · Cited by 20
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence
Bieńkowski, M., Tomasik, B., Braun, M., & Jassem, J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102359 · Cited by 19
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients
Tessari, A., Parbhoo, K., Pawlikowski, M., Fassan, M., Rulli, E., Foray, C., Fabbri, A., Embrione, V., Ganzinelli, M., Capece, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0424-8 · Cited by 18
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Matulonis, U. A., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Berton, D., Berek, J. S., Haslund, C. A., Marmé, F., González-Martín, A., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.03.018 · Cited by 17
RAD51-mediated homologous recombination is a pro-tumour driver pathway
López, B. S. (2025) · Oncogene · doi:10.1038/s41388-025-03583-x · Cited by 17
The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer
Riedel, M., Bronger, H., Magdolen, V., & Dreyer, T. F. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1924680 · Cited by 17
Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy
Ichikawa, H., Aizawa, M., Kano, Y., Hanyu, T., Muneoka, Y., Hiroi, S., Ueki, H., Moro, K., Hirose, Y., Miura, K., et al. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01542-1 · Cited by 17
USP3 promotes DNA damage response and chemotherapy resistance through stabilizing and deubiquitinating SMARCA5 in prostate cancer
Li, S., Li, S., Xiong, S., Li, Z., Yang, H., Yang, H., Xiong, Y., Zhan, X., Dong, Q., Hu, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07117-3 · Cited by 20
Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors
Curigliano, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.004 · Cited by 17
Molecular Features and Clinical Management of Hereditary Gynecological Cancers
Ueki, A., & Hirasawa, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249504 · Cited by 17
BRCA1/2 Signaling and Homologous Recombination Deficiency in Breast and Ovarian Cancer
Royfman, R., Whiteley, E., Noe, O., Morand, S. M., Creeden, J. F., Stanbery, L., Hamouda, D., & Nemunaitis, J. J. (2021) · Future Oncology · doi:10.2217/fon-2021-0072 · Cited by 17
DNA Double Strand Break Repair - Related Synthetic Lethality
Toma, M. M., Skórski, T., & Śliwiński, T. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180201114306 · Cited by 17
Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer
Jiao, X., Liu, J., Wu, Y., Zhong, Q., Zhu, L., Wang, L., Li, H., Xiang, M., Zhao, X., Zhao, G., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu6989 · Cited by 20
Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies
Hein, K. Z., Stephen, B., & Fu, S. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-37 · Cited by 17
Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy
Luo, S., Zhang, Y., Yang, Y., Zhu, S., Liu, W., Zhu, J., Liang, X., Jiang, Z., Sun, S., Hou, X., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.04.695 · Cited by 16
Ovarian Cancer: Molecular Classification and Targeted Therapy
Ravindran, F., & Choudhary, B. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95967 · Cited by 16
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
Sassu, C. M., Palaia, I., Boccia, S. M., Caruso, G., Perniola, G., Tomao, F., Donato, V. D., Musella, A., & Muzii, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413650 · Cited by 16
Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study
Takamatsu, S., Yoshihara, K., Baba, T., Shimada, M., Yoshida, H., Kajiyama, H., Oda, K., Mandai, M., Okamoto, A., Enomoto, T., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02122-9 · Cited by 16
Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression
Lin, T., Lin, T.-C., McGrail, D. J., Bhupal, P. K., Ku, Y.-H., Zhang, W., Meng, L., Lin, S., Peng, G., & Tsai, R. Y. L. (2019) · Oncogene · doi:10.1038/s41388-019-0710-0 · Cited by 18
Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer
Bercow, A. S., & Eisenhauer, E. L. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25645 · Cited by 16
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors
Lee, E. K., & Matulonis, U. A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773791 · Cited by 16
Serotonin-licensed macrophages potentiate chemoresistance via inositol metabolic crosstalk in ovarian cancer
Li, J., Lu, J., Zheng, C., Huang, X., Li, H., Mai, Q., Chen, S., Zhou, Z., Zhu, J., Yu., T. S., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.011 · Cited by 15
The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
Morra, F., Merolla, F., Damia, G. L. M., Ricci, F., Varricchio, S., Ilardi, G., Arenare, L., Califano, D., Napolitano, V., Fruscio, R., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02459-2 · Cited by 15
Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
Roering, P., Siddiqui, A., Heuser, V. D., Potdar, S., Mikkonen, P., Oikkonen, J., Li, Y., Pikkusaari, S., Wennerberg, K., Hynninen, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.954430 · Cited by 15
A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer
Wang, F., Yu, X., Qian, J., Cao, Y., Dong, S., Zhan, S., Lü, Z., Bast, R. C., Song, Q., Chen, Y., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101077 · Cited by 15
BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer
Fiegl, H., Schnaiter, S., Reimer, D., Leitner, K., Nardelli, P., Tsibulak, I., Wieser, V. E., Wimmer, K., Schamschula, E., Marth, C., et al. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01781-0 · Cited by 16
Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer
Alradwan, I. A., Zhi, P., Zhang, T., Lip, H., Zetrini, A., He, C., Henderson, J. T., Rauth, A. M., & Wu, X. Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.061 · Cited by 15
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors
Mukhopadhyay, A., Drew, Y., Matheson, E. C., Salehan, M., Gentles, L., Pachter, J. A., & Curtin, N. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.011 · Cited by 15
Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier
Chen, Y., Wang, Y., Salas, L. A., Miller, T. W., Mark, K. M. K., Marotti, J. D., Kettenbach, A. N., Cheng, C., & Christensen, B. C. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1090-z · Cited by 15
A Potential Role for HUWE1 in Modulating Cisplatin Sensitivity
Wenmaekers, S., Viergever, B. J., Kumar, G., Kranenburg, O., Black, P. C., Daugaard, M., & Meijer, R. P. (2021) · Cells · doi:10.3390/cells10051262 · Cited by 15
PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer
Kraya, A., Maxwell, K. N., Eiva, M. A., Wubbenhorst, B. S., Pluta, J. B., Feldman, M. D., Nayak, A., Powell, D. J., Domchek, S. M., Vonderheide, R. H., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00159 · Cited by 15
Multidisciplinary considerations in the maintenance treatment of poly(ADP‐ribose) polymerase inhibitors for homologous recombination‐proficient, advanced‐stage epithelial ovarian cancer
Cass, I. A., Roberts, J. N. T., Benoit, P. R., & Jensen, N. V. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21764 · Cited by 15
Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?
González-Martı́n, A. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30621-0 · Cited by 15
PARP inhibition in the ovarian cancer patient: Current approvals and future directions
Kurnit, K. C., Avila, M., Hinchcliff, E., Coleman, R. L., & Westin, S. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107588 · Cited by 15
Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
Ngeow, J. Y. Y., Chiang, J., Astiazarán-Symonds, E., Balmañà, J., Cass, I. A., Kommoss, F. K. F., Foulkes, W. D., James, P. A., Katcher, A. H., Klugman, S. D., et al. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101557 · Cited by 16
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
Lu, X. M., He, Y., Johnston, R. L., Nanayakkara, D. M., Sankarasubramanian, S., López, J. A., Friedlander, M. L., Kalimutho, M., Hooper, J. D., Raninga, P. V., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02570-4 · Cited by 14
Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study
Yoshihara, K., Baba, T., Tokunaga, H., Nishino, K., Sekine, M., Takamatsu, S., Matsumura, N., Yoshida, H., Kajiyama, H., Shimada, M., et al. (2023) · Cancer Science · doi:10.1111/cas.15747 · Cited by 14
Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy
Ali, U., Vungarala, S., & Tiriveedhi, V. (2024) · Genes · doi:10.3390/genes15020162 · Cited by 16
Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition
Xi, Q., Kunita, A., Ogawa, M., Ka, M., Tanimoto, S., Tsuchimochi, S., Nagai, S., Matsunaga, A., Fukuda, T., Watanabe, K., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03312-4 · Cited by 14
Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
Teo, M. Y., & O'Reilly, E. M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.05.04 · Cited by 14
Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer
Liu, W., Wang, Z., Ma, J., Hou, Y., Zhao, J., Dong, B., Tu, S., Wang, L., & Guo, Y. (2017) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2017.0104 · Cited by 14
Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties
Mishra, B., Zhang, S., Zhao, H. L., Darżynkiewicz, Z., Lee, E. Y. C., Lee, M., & Zhang, Z. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1529126 · Cited by 14
The emerging role of PARP inhibitors in prostate cancer
Stellato, M., Guadalupi, V., Sepe, P., Mennitto, A., Claps, M., Zattarin, E., Verzoni, E., Valdagni, R., de Braud, F., Santini, D., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1797497 · Cited by 14
Obesity and Energy Substrate Transporters in Ovarian Cancer—Review
Baczewska, M., Bojczuk, K., Kołakowski, A., Dobroch, J., Guzik, P. W., & Knapp, P. (2021) · Molecules · doi:10.3390/molecules26061659 · Cited by 14
PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification
Zhang, X., Wang, A., Han, L. M., Liang, B., Allard, G. M., Diver, E., & Howitt, B. E. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100106 · Cited by 14
Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response
Mann, E. K., Lee, K. J., Chen, D., da Silva, L. M., Zotto, V. L. D., Scalici, J. M., & Gassman, N. R. (2021) · Biology · doi:10.3390/biology10050385 · Cited by 14
Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research
Clark, J. A., Fotopoulou, C., Cunnea, P., & Krell, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837233 · Cited by 17
The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors
Beneyton, A., Nonfoux, L., Gagné, J., Rodrigue, A., Kothari, C., Atalay, N., Hendzel, M. J., Poirier, G. G., & Masson, J. (2023) · NAR Cancer · doi:10.1093/narcan/zcad043 · Cited by 14
FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer
Huang, Y.-Z., Sang, M., Xi, P.-W., Xu, R.-X., Cai, M., Wang, Z.-W., Zhao, J., Li, Y.-H., Yin, P., Ding, Q., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2738 · Cited by 13
Role of PARP-1 structural and functional features in PARP-1 inhibitors development
Merkuryev, A. V., & Egorov, V. V. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108188 · Cited by 13
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
Capellero, S., Erriquez, J., Melano, C., Mesiano, G., Genta, S., Pisacane, A. M., Mittica, G., Ghisoni, E., Olivero, M., Renzo, M. F. D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63634-z · Cited by 13
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
den Ouden, J. E., Zaman, G. J. R., Dylus, J., van Doornmalen, A. M., Mulder, W. R., Grobben, Y., van Riel, W. E., de Hullu, J. A., Buijsman, R. C., & van Altena, A. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27827 · Cited by 13
Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
Kristeleit, R. S., & Moore, K. N. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.003 · Cited by 13
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway
Yanaihara, N., Yoshino, Y., Noguchi, D., Tabata, J., Takenaka, M., Iida, Y., Saito, M., Yanagida, S., Iwamoto, M., Kiyokawa, T., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.11.006 · Cited by 13
Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer
Muaibati, M., Abasi, A., Zhang, T., Dai, Y., Li, R., Huang, F., Li, K., Tong, Q., Huang, X., & Zhuang, L. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.3 · Cited by 13
The potential of PARP as a therapeutic target across pediatric solid malignancies
Keller, K. M., Koetsier, J., Schild, L. G., Amo-Addae, V., Eising, S., van den Handel, K., Ober, K., Koopmans, B., Essing, A. H. W., van den Boogaard, M. L., et al. (2023) · BMC Cancer · doi:10.1186/s12885-022-10319-7 · Cited by 13
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
Lenz, L. H., Neff, C. D., Solimeno, C., Cogan, E. S., Abramson, V. G., Boughey, J. C., Falkson, C. I., Goetz, M. P., Ford, J. M., Gradishar, W. J., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07046-3 · Cited by 13
Cancer genomics guide clinical practice in personalized medicine
Lehmann‐Che, J., Poirot, B., Boyer, J.-C., & Evrard, A. (2017) · Therapies · doi:10.1016/j.therap.2016.09.015 · Cited by 14
Rucaparib in Ovarian Cancer: Extending the Use of PARP Inhibitors in the Recurrent Disease
Molin, G. Z. D., Westin, S. N., & Coleman, R. L. (2018) · Future Oncology · doi:10.2217/fon-2018-0215 · Cited by 13
Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1
Baloch, T., López‐Ozuna, V. M., Wang, Q., Matanis, E., Kessous, R., Kogan, L., Yasmeen, A., & Gotlieb, W. H. (2019) · BMC Cancer · doi:10.1186/s12885-018-5250-4 · Cited by 13
Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women
Filippova, O. T., Selenica, P., Pareja, F. G., Vahdatinia, M., Zhu, Y., Pei, X., Riaz, N., Roche, K. L., Dennis, S., Abu‐Rustum, N. R., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.02.028 · Cited by 13
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer
Longoria, T. C., & Tewari, K. S. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461838 · Cited by 13
Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid
Roussel-Simonin, C., Blanc‐Durand, F., Tang, R., Vasseur, D., Formal, A. L., Chardin, L., Yaniz‐Galende, E., Gouy, S., Maulard, A., Scherier, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01864-1 · Cited by 12
PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation
Muvaffak, A., & Coleman, K. G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380633 · Cited by 12
Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization Project
Andrews, H. S., McShane, L. M., Kohn, E. C., Arend, R. C., Karlovich, C., Kincaid, K., Laird, A., Li, M., Sokol, E. S., Starks, E. R., et al. (2024) · JCO oncology advances. · doi:10.1200/oa-24-00042 · Cited by 12
Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
Xiao, Y., Wu, Y., Wang, Q., Li, M., Deng, C., & Gu, X. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02056-8 · Cited by 12
The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer
Jiang, B., Shang, Y., Zhang, X., He, W., Hua, H., Ye, F., Zhou, X., Li, Y., Zhong, W., Jiang, W., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf141 · Cited by 12
p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1–driven ovarian cancers
Sine, C. C., Watts, L. P., Fernandez, B., Marikar, N. C., Wang, J., Knudsen, E. S., Witkiewicz, A. K., & Spencer, S. L. (2025) · Science Signaling · doi:10.1126/scisignal.adv0415 · Cited by 12
BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling
Bradbury, M., Borràs, E., Castellví, J., Méndez, O., Sánchez-Iglesias, J. L., Pérez‐Benavente, A., Gil‐Moreno, A., Sabidó, E., & Santamaría, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-08461-0 · Cited by 12
Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
Jin, N. Y., Xia, Y., & Gao, Q. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5476 · Cited by 12
Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair
Yi, J., Luo, X., Xing, J., Gedanken, A., Lin, X., Zhang, C., & Qiao, G. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10507 · Cited by 12
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
Yang, S., Green, A., Virani, N. A., Robinson, A., Senat, M., Testino, B., Dinulescu, D. M., & Sridhar, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1175617 · Cited by 12
Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
Lampert, E. J., Hays, J. L., Kohn, E. C., Annunziata, C. M., Minasian, L. M., Yu, M., Gordon, N., Sissung, T. M., Chiou, V. L., Figg, W. D., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26869 · Cited by 12
Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
Shimomura, A., Yonemori, K., Yoshida, M., Yoshida, T., Yasojima, H., Masuda, N., Aogi, K., Takahashi, M., Naito, Y., Shimizu, S., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.07.013 · Cited by 12
Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer
Evangelisti, G., Barra, F., Moioli, M., Sala, P., Stigliani, S., Gustavino, C., Costantini, S., & Ferrero, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1783238 · Cited by 12
Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
Guffanti, F., Alvisi, M. F., Caiola, E., Ricci, F., Maglie, M. D., Soldati, S., Ganzinelli, M., Decio, A., Giavazzi, R., Rulli, E., et al. (2020) · Cancers · doi:10.3390/cancers12092398 · Cited by 12
Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma
Stover, E. H., Feltmate, C. M., Berkowitz, R. S., Lindeman, N. I., Matulonis, U. A., & Konstantinopoulos, P. A. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00135 · Cited by 12
Self-citation
Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy
Watanabe, K., Kosaka, T., Aimono, E., Hongo, H., Mikami, S., Nishihara, H., & Oya, M. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.06.005 · Cited by 12
Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition
Lin, X., Soni, A., Hessenow, R. K., Sun, Y., Mladenov, E., Guberina, M., Stuschke, M., & Iliakis, G. E. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110475 · Cited by 11
Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer
Sullivan, M. W., Graves, S. M., Adkoli, A., Zhou, Q., Iasonos, A. E., Ellenson, L. H., Dennis, S., Aghajanian, C. A., Liu, Y. L., Sonoda, Y., et al. (2024) · Cancer · doi:10.1002/cncr.35523 · Cited by 11
HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond
Minisini, M., Mascaro, M., & Brancolini, C. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.103 · Cited by 11
DNA methylation marker to estimate ovarian cancer cell fraction
Ebata, T., Yamashita, S., Takeshima, H., Yoshida, H., Kawata, Y., Kino, N., Yasugi, T., Terao, Y., Yonemori, K., Kato, T., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01679-y · Cited by 11
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
Affatato, R., Chiappa, M., Guffanti, F., Ricci, F., Formenti, L., Fruscio, R., Jaconi, M., Ridinger, M., Erlander, M. G., & Damia, G. L. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221095064 · Cited by 11
Somatic Variants in DNA Damage Response Genes in Ovarian Cancer Patients Using Whole-exome Sequencing
Lopacinska‐Jørgensen, J., Oliveira, D. V. N. P., Poulsen, T. S., Høgdall, C. K., & Høgdall, E. V. S. (2023) · Anticancer Research · doi:10.21873/anticanres.16348 · Cited by 11
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
Machino, H., Dozen, A., Konaka, M., Komatsu, M., Nakamura, K., Ikawa, N., Shozu, K., Asada, K., Kaneko, S., Yoshida, H., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01090-1 · Cited by 11
HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma
Koskela, H., Li, Y., Joutsiniemi, T., Muranen, T., Isoviita, V., Huhtinen, K., Micoli, G., Lavikka, K., Marchi, G., Hietanen, S., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.11.027 · Cited by 11
Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent
Toma, M. M., Witusik‐Perkowska, M., Szwed, M., Stawski, R. S., Szemraj, J., Drzewiecka, M., Nieborowska-Skorska, M., Radek, M., Kolasa, P., Matlawska‐Wasowska, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26409 · Cited by 11
Clarifying the role of EMSY in DNA repair in ovarian cancer
Kondrashova, O., & Scott, C. L. (2019) · Cancer · doi:10.1002/cncr.32135 · Cited by 11
Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma
Zeng, X., Baba, T., Hamanishi, J., Matsumura, N., Kharma, B., Mise, Y., Abiko, K., Yamaguchi, K. D., Horikawa, N., Hunstman, D. G., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32501 · Cited by 11
Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
Bouberhan, S., Philp, L., Hill, S. J., Al-Alem, L., & Rueda, B. R. (2020) · Cancers · doi:10.3390/cancers12051206 · Cited by 12
Integrating PARP inhibitors into the management of breast cancer: where are we?
Azim, H. A., Kassem, L. M. H., & Azim, H. A. (2021) · Chinese Clinical Oncology · doi:10.21037/cco-19-230 · Cited by 11
Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray
Wang, S., Yin, C., Zhang, Y., Zhang, L., Lin, T., Liang, W., Pang, L., Fu, R., Ding, Y., Li, F., et al. (2019) · BioMed Research International · doi:10.1155/2019/2867372 · Cited by 11
IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma
Liu, M., Zhang, Y., Wu, Y., Jin, J., Cao, Y., Fang, Z., Geng, L., Yang, L., Yu, M., Bu, Z., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70960 · Cited by 10
LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer
Dey, G., Bharti, R., Braley, C., Alluri, R. K., Esakov, E. L., Crean-Tate, K., McCrae, K. R., Joehlin-Price, A. S., Rose, P. G., Lathia, J. D., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01194-2 · Cited by 11
A comprehensive pan-cancer analysis of RNF187 in human tumors
Zhang, X., Zhang, X., Liu, T., & Sha, K. (2025) · Discover Oncology · doi:10.1007/s12672-025-01795-x · Cited by 10
Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images
Zhang, K., Qiu, Y., Feng, S., Yin, H., Liu, Q., Zhu, Y., Cui, H., Wei, X., Wang, G., Wang, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06234-7 · Cited by 10
BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis
Tsuchimochi, S., Yamamoto, Y., Taguchi, A., Kawazu, M., Sone, K., Ikemura, M., Tamai, K., Kitamura, S., Yoshimoto, D., Fukaya, S., et al. (2025) · Cancer Science · doi:10.1111/cas.70078 · Cited by 10

Authors: Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
Affiliations: Harvard University (US)
2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Konstantinopoulos, Panagiotis A.
ORCID: Konstantinopoulos, Panagiotis A.
Shapiro, Geoffrey I.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-11-01
Volume: 5
Issue: 11
Pages: 1137-1154
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0714
PMC: PMC4631624
OpenAlex: W2179105349
Cited by: 945
References: 180
Citations by year: 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
MeSH terms: Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks